文献速递肝病

肝硬化急性失代偿中肝功能障碍与全身炎症驱动器官衰竭:一项多中心研究

Liver Dysfunction and Systemic Inflammation Drive Organ Failures in Acute Decompensation of Cirrhosis: A Multicentric Study.
PubMed 文献 · Am J Gastroenterol · 2024-10-04

这项在印度北部、南部和东部开展的多中心前瞻性研究纳入625例肝硬化急性失代偿患者,分为推导队列318例和验证队列307例,32.2%进展为慢加急性肝衰竭。进展者胆红素、白细胞、INR和MELD 3.0更高而血钠和生存率更低,入院时肝衰竭及7天内胆红素、INR、MELD 3.0轨迹可显著预测进展,新模型预测能力优于MELD 3.0和CLIF-AD评分。

要点

  • 625例肝硬化急性失代偿患者中32.2%进展为慢加急性肝衰竭。
  • 入院时肝衰竭预测ACLF进展的OR在推导队列为2.4、验证队列为6.9。
  • 新pre-ACLF模型AUC在推导队列0.71、验证队列0.82,优于MELD 3.0和CLIF-AD评分。

核心结论

  • 该印度队列中约三分之一的急性失代偿患者快速进展为慢加急性肝衰竭并导致高死亡率,早期识别高危患者可指导针对性干预以预防ACLF。

研究设计与样本

  • 多中心前瞻性研究,历时2年,从印度北部、南部和东部纳入625例符合欧洲肝病学会标准的肝硬化急性失代偿患者。
  • 队列分为推导队列318例和验证队列307例,收集临床、生化及90天生存数据,推导并验证pre-ACLF预测模型,与MELD 3.0和CLIF-AD评分比较。

主要发现

  • 625例患者平均年龄49岁,83%为男性,77.5%为酒精相关性肝病,32.2%进展为ACLF。
  • 推导队列中进展者胆红素10.9 vs 8.1 mg/dL、白细胞9,400 vs 8,000 per mm³、INR 1.9 vs 1.8、MELD 3.0 28 vs 25均高于未进展者,血钠131 vs 134 mEq/L和生存率62% vs 86%低于未进展者(P < 0.05)。
  • 验证队列中酒精相关性肝炎、感染和肝性脑病为额外危险因素,结果与推导队列一致。
  • 入院时肝衰竭预测ACLF进展的OR在推导队列为2.4、验证队列为6.9,7天内胆红素、INR和MELD 3.0轨迹显著预测ACLF进展(P < 0.001)。
  • 新pre-ACLF模型AUC在推导队列为0.71、验证队列为0.82,优于MELD 3.0和CLIF-AD评分(P < 0.05)。

临床怎么用

  • 作者认为早期识别有ACLF风险的患者可指导针对性干预以预防ACLF。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hospitalized patients with acute decompensation (AD) of cirrhosis are at risk of progressing to acute-on-chronic liver failure (ACLF), significantly increasing their mortality. The aim of this study was to identify key predictors and patient trajectories predisposing to ACLF. METHODS: In this multicenter, prospective study spanning 2 years, clinical, biochemical, and 90-day survival data were collected from 625 patients with AD (European Association for the Study of the Liver criteria) across North, South, and East India. We divided the cohort into a Derivation cohort (DC: 318 patients) and a Validation cohort (VC: 307 patients). Predictive models for pre-ACLF were derived, validated, and compared with established scores such as model for end-stage liver disease (MELD) 3.0 and chronic liver failure Consortium acute decompensation. RESULTS: Of 625 patients (mean age 49 years, 83% male, 77.5% with alcohol-related liver disease), 32.2% progressed to ACLF. Patients progressing to ACLF showed significantly higher bilirubin (10.9 vs 8.1 mg/dL), leukocyte counts (9,400 vs 8,000 per mm 3 ), international normalized ratio (1.9 vs 1.8), and MELD 3.0 (28 vs 25) but lower sodium (131 vs 134 mEq/L) and survival (62% vs 86%) compared with those without progression ( P < 0.05) in the DC. Consistent results were noted with alcohol-associated hepatitis, infection and hepatic encephalopathy as additional risk factors in VC. Liver failure at presentation (odds ratio: 2.4 [in DC], 6.9 [in VC]) and the 7-day trajectories of bilirubin, international normalized ratio, and MELD 3.0 significantly predicted ACLF progression ( P < 0.001). A new pre-ACLF model showed superior predictive capability (area under the curve of 0.71 in DC and 0.82 in VC) compared with MELD 3.0 and chronic liver failure Consortium acute decompensation scores ( P < 0.05). DISCUSSION: Approximately one-third of AD patients in this Indian cohort rapidly progressed to ACLF, resulting in high mortality. Early identification of patients at risk can guide targeted interventions to prevent ACLF.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Verma N, Roy A, Valsan A, et al. Liver Dysfunction and Systemic Inflammation Drive Organ Failures in Acute Decompensation of Cirrhosis: A Multicentric Study. Am J Gastroenterol. 2024. PMID: 39364890. doi:10.14309/ajg.0000000000003115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。